Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab in Systemic Lupus Erythematosus (SOLUNA)
NCT07598396Phase 2Recruiting
- Sponsor
- Roche
- Start
- May 2026
- Primary completion
- Feb 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of mosunetuzumab in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Roche. Primary endpoint: Proportion of participants who have achieved remission at 76 weeks. Started May 2026; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07598396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07598396.